Claims:

1. Use of a proton pump inhibitor in the manufacture of a medicament for the treatment or prophylaxis of a cancerous condition, further comprising an antacid.

2. Use according to claim 1, wherein the condition is a tumour.

3. Use according to claim 2, wherein the tumour is metastatic.

4. Use according to any preceding claim, wherein the proton pump inhibitor is a 2-pyridyl methylsulphinyl benzimidazole proton pump inhibitor.

5. Use according to claim 4, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and mixtures thereof.

6. Use according to any preceding claim, wherein the medicament is for oral administration and is for the treatment of a patient who has been treated with an antacid sufficient to prevent total sequestration of the PPI in the stomach of the patient.

7. Use according to claim 5 or 6, wherein the antacid is formulated for administration prior to the proton pump inhibitor.

8. Use according to any of claims 5 to 7, wherein the antacid is calcium carbonate.

9. Use according to any of claims 5 to 7, wherein the antacid is an H_2-receptor antagonist.

10. Use of a proton pump inhibitor in the manufacture of a medicament for combination therapy or prophylaxis of a disease condition, wherein the proton pump inhibitor is administered prior to at least one further drug indicated against said condition.

11. Use according to claim 10, wherein administration of the proton pump inhibitor is sufficiently prior to the administration of the further drug as to reduce the acidity associated with the site of the said condition.

12. Use according to claim 10 or 11, wherein the period prior to administration of the further drug is between 30 minutes and 3 days.

13. Use according to any of claims 10 to 12, wherein the further drug is selected from: vinka alkaloids; taxanes; anthracyclines; anthracenes; epipodophyllotoxins; camptothecins; heavy metal oxyanions; actinomycin d; mitomycin c; methotrexate; trimetrexate; amsacrine; imitinib; and melphalan; 5-fluorouracil; and cisplatin.

14. Use according to any of claims 10 to 13, wherein the disease condition is resistant to the further drug, and the proton pump inhibitor medicament is for administration at a time when levels of the further drug are clinically sub-effective.

15. Use according to claim 14, wherein the disease condition is a cancerous condition.

16. Use according to claim 15, wherein the condition is a tumour.

17. Use according to claim 16, wherein the tumour is metastatic.

18. Use according to claim 14, wherein the disease condition is selected from AIDS, rheumatoid arthritis, ulcerative colitis, Crohn's disease, or combinations thereof.

19. Use according to claim 18, wherein the condition is AIDS, and the further drug is an HAART drug.

20. Use according to any of claims 10 to 19, wherein the proton pump inhibitor is a 2-pyridyl methylsulphinyl benzimidazole proton pump inhibitor.

21. Use according to claim 20, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and mixtures thereof.

22. Use according to any of claims 10 to 21, further comprising an antacid.

23. Use according to any preceding claim, wherein the proton pump inhibitor is omeprazole.

24. Use according to any preceding claim, wherein the medicament is for the treatment of the condition.